Online inquiry

IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8976MR)

This product GTTS-WQ8976MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL22 gene. The antibody can be applied in Inflammatory conditions research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_020525.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 50616
UniProt ID Q9GZX6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ8976MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5718MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CEA TCB
GTTS-WQ9070MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMC-A12
GTTS-WQ7117MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FE 999302
GTTS-WQ12055MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ15476MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA UCB-0107
GTTS-WQ14074MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-3918
GTTS-WQ5360MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ15673MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA VB6-845
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW